|
|
GRI Indicators
(Italicized indicators are considered
non-core by the GRI and do not require reporting)
|
Addressed in CR web section or www.merck.com |
|
ECONOMIC
|
|
DMA
|
Disclosure of management approach for economic performance
|
Our Economic Impact
Valuing Our Employees
Our Impact on Local Communities
Improving Access to Medicines, Vaccines and Health Care
|
|
GRI EC1
|
Direct economic value generated and distributed, including revenues, operating costs, employee compensation, donations and other community investments, retained earnings, and payments to capital providers and governments
|
Our Economic Impact
Valuing Our Employees
Our Impact on Local Communities
Improving Access to Medicines, Vaccines and Health Care
|
|
GRI EC2
|
Financial implications and other risks and opportunities for the organization's activities due to climate change
|
We do not currently report on this core indicator in our CR report.
|
|
GRI EC3
|
Coverage of the organization's defined benefit plan obligations
|
pp.123-132 of our Annual Financial Report (10K) in 2007 and pp.109-114 in 2006.
|
|
GRI EC4
|
Significant financial assistance received from government
|
We do not currently report on this non-core indicator.
|
|
GRI EC5
|
Range of ratios of standard entry level wage compared to local minimum wage at significant locations of operation
|
We do not currently report on this non-core indicator.
|
|
GRI EC6
|
Policy, practices and proportion of spending on locally-based suppliers at significant locations of operation
|
Partially addressed: Managing Our External Suppliers
|
|
GRI EC7
|
Procedures for local hiring and proportion of senior management hired from the local community at significant locations of operation
|
Partially addressed: Promoting Diversity and Inclusion
|
|
GRI EC8
|
Development and impact of infrastructure investments and services provided primarily for public benefit through commercial, in-kind or probono engagement
|
Improving Access to Medicines, Vaccines and Health Care
Fostering Science Education
Our Impact on Local Communities
|
|
GRI EC9
|
Understanding and describing significant indirect economic impacts, including the extent of impacts
|
Improving Access to Medicines, Vaccines and Health Care Fostering Science Education
Our Impact on Local Communities
|
|
PRODUCT
|
|
DMA
|
Disclosure of management approach for product performance
|
Ensuring Confidence in the Safety and Quality of Our Products
Product Stewardship
|
|
GRI PR1
|
Life cycle stages in which health and safety impacts of products and services are assessed for improvement, and percentage of significant products and services categories subject to such procedures
|
Ensuring Confidence in the Safety and Quality of Our Products
Product Stewardship
|
|
GRI PR2
|
Total number of incidents of non-compliance with regulations and voluntary codes concerning health and safety impacts of products and services, by type of outcomes
|
We do not currently report on this non-core indicator.
|
|
GRI PR3
|
Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirements
|
Ensuring Confidence in the Safety and Quality of Our Products
Clinical Trial Registration and Disclosure of Clinical Trials Results
Ethical Sales & Marketing Practices
|
|
GRI PR4
|
Total number of incidents of non-compliance with regulations and voluntary codes concerning product and service information, and labeling, by type of outcomes
|
We do not currently report on this non-core indicator.
|
|
GRI PR5
|
Practices related to customer satisfaction, including results of surveys measuring customer satisfaction
|
We do not currently report on this non-core indicator.
|
|
GRI PR 6
|
Programs for adherence to laws, standards and voluntary codes related to marketing communications, including advertising, promotion and sponsorship
|
Ethical Sales & Marketing Practices
|
|
GRI PR7
|
Total number of incidents of non-compliance with regulations and voluntary codes concerning marketing communications, including advertising, promotion and sponsorship, by type of outcomes
|
We do not currently report on this non-core indicator.
|
|
GRI PR8
|
Total number of substantiated complaints regarding breaches of customer privacy and losses of customer data
|
We do not currently report on this non-core indicator.
|
|
GRI PR9
|
Monetary value of significant fines for non-compliance with laws and regulations concerning the provision and use of products and services
|
Ethical Sales & Marketing Practices
|
|
ENVIRONMENTAL
|
|
DMA
|
Disclosure of management approach for environmental performance
|
Managing Our Environmental Footprint
|
|
GRI EN1
|
Materials used by weight or volume
|
Partially addressed in: Emissions, Effluents & Waste
|
|
GRI EN2
|
Percentage of materials used that are recycled input materials
|
Partially addressed in: Emissions, Effluents & Waste
|
|
GRI EN3
|
Direct energy consumption by primary energy source
|
Energy Use and Climate Change
|
|
GRI EN4
|
Indirect energy consumption by primary energy source
|
Partially addressed in: Energy Use and Climate Change
|
|
GRI EN5
|
Energy saved due to conservation and efficiency improvements
|
Energy Use and Climate Change
|
|
GRI EN6
|
Initiatives to provide energy-efficient or renewable energy-based products and services, and reductions in energy requirements as a result of these initiatives
|
We do not report on this non-core indicator because it is not relevant to pharmaceutical products.
|
|
GRI EN7
|
Initiatives to reduce indirect consumption and reductions achieved
|
Energy Use and Climate Change
|
|
GRI EN8
|
Total water withdrawal by source
|
Water Use
|
|
GRI EN9
|
Water sources significantly affected by withdrawal of water
|
We do not currently report on this non-core indicator.
|
|
GRI EN10
|
Percentage and total volume of water recycled and reused
|
We do not currently report on this core indicator.
|
|
GRI EN11
|
Location and size of land owned, leased, managed in or adjacent to, protected areas and areas of high biodiversity value outside protected areas
|
We do not currently report on this core indicator.
|
|
GRI EN12
|
Description of significant activities, products and service on biodiversity in these areas.
|
We do not currently report on this core indicator. Merck has discontinued bioprospecting.
|
|
GRI EN13
|
Habitats protected or restored
|
We do not currently report on this non-core indicator. We discuss habitat projects in Our Impact on Local Communities
|
|
GRI EN14
|
Strategies, current actions and future plans for managing impacts on biodiversity
|
We do not currently report on this non-core indicator.
|
|
GRI EN15
|
Number of IUCN Red List species and national conservation list species with habitats in areas affected by operations, by level of extinction risk
|
We do not currently report on this non-core indicator.
|
|
GRI EN16
|
Total direct and indirect GHG emissions by weight
|
Energy Use and Climate Change
|
|
GRI EN17
|
Other relevant indirect GHG emissions by weight
|
We do not currently report on Scope 3 indirect GHG emissions.
|
|
GRI EN18
|
Initiatives to reduce GHG emissions and reductions achieved
|
Energy Use and Climate Change
|
|
GRI EN19
|
Emissions of ozone-depleting substances by weight
|
Emissions, Effluents & Waste
|
|
GRI EN20
|
NOx, SOx and other significant air emissions by type and weight
|
Emissions, Effluents & Waste
|
|
GRI EN21
|
Total water discharge by quality and destination
|
We do not currently report on this core indicator.
|
|
GRI EN22
|
Total weight of waste by type and disposal method
|
Emissions, Effluents & Waste
|
|
GRI EN23
|
Total number and volume of significant spills
|
Partially addressed: Safety and Environmental Compliance & Management
|
|
GRI EN24
|
Weight of transported, imported, exported or treated waste deemed hazardous under the terms of the Basel Convention Annex I, II, III and VIII, and percentage of transported waste shipped internationally
|
We do not currently report on this non-core indicator.
|
|
GRI EN25
|
Identity, size, protected status, and biodiversity value of water bodies and related habitats significantly affected by the reporting organization's discharges of water and runoff
|
We do not currently report on this non-core indicator.
|
|
GRI EN26
|
Initiatives to mitigate environmental impacts of products and services, and extent of impact mitigation
|
Partially addressed in:
Product Stewardship
|
|
GRI EN27
|
Percentage of products sold and their packaging materials that are reclaimed by category
|
We do not currently report on this core indicator. Our products are consumed when used. Unsold product is reclaimed and destroyed, Packaging is not currently being reclaimed.
|
|
GRI EN28
|
Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with environmental laws and regulation
|
Safety and Environmental Compliance & Management
|
|
GRI EN29
|
Significant environmental impacts of transporting products and other goods and materials used for the organization's operations, and transporting members of the workforce
|
We do not currently report on this non-core indicator.
|
|
GRI EN30
|
Total environmental protection expenditures and investments by type
|
We do not currently report on this non-core indicator.
|
|
LABOR
|
|
DMA
|
Disclosure of management approach for labor-related performance
|
Valuing Our Employees
|
|
GRI LA1
|
Total workforce by employment type, employment contract and region
|
Partially addressed in:
Building a Positive Working Environment
|
|
GRI LA2
|
Total number and rate of employee turnover by age group, gender and region
|
Partially addressed in:
Building a Positive Working Environment
|
|
GRI LA3
|
Benefits provided to full-time employees that are not provided to temporary or part-time employees, by major operations
|
Partially addressed in:
Building a Positive Working Environment
|
|
GRI LA4
|
Percentage of employees covered by collective bargaining agreements
|
Human Rights of Our Employees
|
|
GRI LA5
|
Minimum notice periods regarding significant operational changes, including whether it is specified in collective agreements
|
Building a Positive Working Environment
|
|
GRI LA6
|
Percentage of total workforce represented in formal joint management-worker health and safety committees that help monitor and advise on occupational health and safety programs
|
Partially addressed in:
Fostering the Health and Safety of Our Employees
|
|
GRI LA7
|
Rates of injury, occupational diseases, lost days and absenteeism, and total number of work-related fatalities per region
|
Partially addressed in:
Fostering the Health and Safety of Our Employees
|
|
GRI LA8
|
Education, training, counseling, prevention and risk-control programs in place to assist workforce members, their families or community members regarding serious diseases
|
Fostering the Health of Our Employees
|
|
GRI LA9
|
Health and safety topics covered in formal agreements with trade unions
|
We do not currently report on this non-core indicator.
|
|
GRI LA10
|
Average hours of training per year per employee per category
|
Partially addressed: Conducting Ourselves Ethically and Transparently
Managing Our Environmental Footprint
The Safety of our Employees
Researching New Medicines and Vaccines to Address Unmet Needs
Building a Positive Working Environment
|
|
GRI LA11
|
Programs for skills management and lifelong learning that support the continued employability of employees and assist them with managing career endings
|
Partially addressed in:
Building a Positive Working Environment
|
|
GRI LA12
|
Percentage of employees receiving regular performance and career development reviews
|
Building a Positive Working Environment
|
|
GRI LA13
|
Composition of governance bodies and breakdown of employees per category according to gender, age group, minority group membership and other diversity indicators
|
Partially addressed: Promoting Diversity and Inclusion
|
|
GRI LA14
|
Ratio of basic salary of men to women by employee category
|
We do not currently report on this core indicator.
|
|
SOCIAL
|
|
DMA
|
Disclosure of management approach for social performance
|
Our Economic Impact
Valuing Our Employees
Our Impact on Local Communities
Improving Access to Medicines, Vaccines and Health Care
Managing Our Environmental Footprint
Conducting Ourselves Ethically and Transparently
Researching New Medicines and Vaccines to Address Unmet Needs
Advocacy and Outreach
|
|
GRI SO1
|
Nature, scope and effectiveness of any programs and practices that assess and manage the impacts of operations on communities, including entering, operating and exiting
|
Our Impact on Local Communities
Managing Our Environmental Footprint
Neighbor of Choice
|
|
GRI SO2
|
Percentage and total number of business units analyzed for risks related to corruption
|
Partially addressed: Conducting Ourselves Ethically and Transparently
|
|
GRI SO3
|
Percentage of employees trained in the organization's anti-corruption policies and procedures
|
Conducting Ourselves Ethically and Transparently
|
|
GRI SO4
|
Actions taken in response to incidents of corruption
|
Partially addressed: Conducting Ourselves Ethically and Transparently
Researching New Medicines and Vaccines to Address Unmet Needs
|
|
GRI SO5
|
Public policy positions and participation in public policy development and lobbying
|
Advocacy and Outreach, with specific positions detailed in all the major sections
|
|
GRI SO6
|
Total value of financial and in-kind contributions to political parties, politicians and related institutions, by country
|
Advocacy and Outreach
|
|
GRI SO7
|
Total number of legal actions for anti-competitive behavior, anti-trust and monopoly practices, and their outcomes
|
pp.24-40 of our Annual Financial Report (10-K) in 2007 and pp22-35 in 2006
|
|
GRI SO8
|
Monetary value of significant fines and total number of non-monetary sanctions for non-compliance with laws and regulations
|
Safety & Environmental Compliance and Management
Conducting Ourselves Ethically and Transparently
|
|
HUMAN RIGHTS
|
|
DMA
|
Disclosure of management approach to human rights performance
|
Promoting and Protecting Human Rights
|
|
GRI HR1
|
Percentage and total number of significant investment agreements that include human rights clauses or that have undergone human rights screening
|
Partially addressed: Managing Our External Suppliers
Researching New Medicines and Vaccines to Address Unmet Needs
|
|
GRI HR2
|
Percentage of significant suppliers and contractors that have undergone screening on human rights, and actions taken
|
Partially addressed: Managing Our External Suppliers
|
|
GRI HR3
|
Total hours of employee training on policies and procedures concerning aspects of human rights that are relevant to operations, including the percentage of employees trained
|
Partially addressed: Conducting Ourselves Ethically and Transparently
|
|
GRI HR4
|
Total number of incidents of discrimination and actions taken
|
We do not report on this core indicator.
|
|
GRI HR5
|
Operations identified in which the right to exercise freedom of association and collective bargaining may be at significant risk, and actions taken to support these rights
|
Promoting and Protecting Human Rights
|
|
GRI HR6
|
Operations identified as having significant risk for incidents of child labor, and measures taken to contribute to the elimination of child labor
|
Promoting and Protecting Human Rights
|
|
GRI HR7
|
Operations identified as having significant risk for incidents of forced or compulsory labor, and measures taken to contribute to the elimination of forced or compulsory labor
|
Promoting and Protecting Human Rights
|
|
GRI HR8
|
Percentage of security personnel trained in the organization's policies and procedures concerning aspects of human rights that are relevant to operations
|
We do not currently report on this non-core indicator.
|
|
GRI HR9
|
Total number of incidents or violations involving rights of indigenous people, and actions taken
|
We do not currently report on this non-core indicator.
|